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ABSTRACT: Artificial metalloenzymes (ArMs), which com-
bine an abiotic metal cofactor with a protein scaffold, catalyze 
various synthetically useful transformations. To complement the 
natural enzymes’ repertoire, effective optimization protocols to 
improve ArM’s performance are required. Here we report on our 
efforts to optimize the activity of an artificial transfer hydrogenase 
(ATHase) using E. coli whole cells. For this purpose, we rely on a 
self-immolative quinolinium substrate which, upon reduction, 
releases fluorescent umbelliferone, thus allowing efficient screen-
ing. Introduction of a loop in the immediate proximity of the Ir-
cofactor afforded an ArM with up to fivefold increase in transfer 
hydrogenation activity compared to the wild-type ATHase using 
purified mutants.  
Enzyme engineering is a powerful means to optimize perfor-
mance of proteins.1–5 Both natural and artificial enzymes have 
been engineered to catalyze a variety of new-to-nature reactions.6–
15 Artificial metalloenzymes (ArMs) result from the introduction 
of an abiotic metallocofactor within a protein scaffold. In this 
context, hemoproteins,16–18 streptavidin (Sav hereafter),7,19 and Pfu 
prolyl-oligopeptidase11,12 have proven versatile. The most active 
ArM reported rely on precious metal cofactors, which are fre-
quently poisoned by of thiols.20–23 Critical analysis of a typical 
workflow for the directed evolution of ArMs reveals the following 
bottlenecks: i) Need to perform catalysis using (partially) purified 
protein samples. Such samples lack a phenotype-genotype link-
age, which is critical in high throughput campaigns ii) Extraction 
and HPLC analysis is often time-consuming.  
We report our efforts to address both challenges by i) com-
partmentalizing an artificial transfer-hydrogenase (ATHase here-
after) in the periplasm of E. coli, thus allowing to maintain the 
phenotype-genotype linkage and ii) relying on a self-immolative 
substrate that releases a fluorophore upon reduction of its iminium 
moiety. In a related context, Lo and coworkers reported on a 
bodipy-flanked aldehyde which, upon reduction by an Ir-
pianostool in mammalian cells, leads to the generation of a fluo-
rescent signal.24 
Self-immolative substrates consist of a cap, a self-immolative 
core and a leaving group, Figure 1a.25,26 Self-immolative sub-
strates have found wide applications in bioanalysis,27 prodrugs,28,29 
high-throughput screening or biomolecular imaging30 etc. We 
hypothesized that a quinolinium substrate, which upon N=C 
reduction, may undergo self-immolation to release a fluorophore 
via the formation of iminoquinone-methide intermediate 3,31 
Figure 1b. The resulting electrophilic intermediate 3 reacts with 
nucleophiles in solution (either water or nucleophilic aminoacid 
residues present on the surface of the protein).32 
 
Figure 1. (a) Self-immolative substrate. (b) Reduction of the 
quinolinium moiety in substrate 1 leads to the release of umbellif-
erone 2 which can be detected by fluorescence. 
 
We selected the biotin-streptavidin couple to ensure localiza-
tion of the Ir-based ATHase cofactor.33–38 Analysis of the various 
X-ray structures of [Cp*Ir(biot-p-L)Cl]   Sav,39,40 reveals that the 
cofactor, located in the biotin-binding vestibule, is solvent ex-
posed. Introduction of additional structural elements around the 
biotin-binding vestibule may have a significant impact on the 
catalytic performance.41 Thanks to its stability and plasticity, we 
have shown that Sav is remarkably tolerant towards the modifica-
tion of its loops.42 Having reported that mutations within the 7,8-
loop (i.e. between residues 112 and 124, especially positions S112 
and K121) significantly affect catalytic performance of various 
ArMs based on the biotin-streptavidin technology,43,44 we selected 
a 24-residue helix-turn-helix motif designed by the Baker 
group45,46 (FPD, Figure 2a), and inserted it between residues 115 
and 117 of Sav, Figure 2. We hypothesized that the insertion of a 
motif in the proximity of the metal cofactor may significantly 
influence the catalytic performance of the ArM. The FPD-chimera 
could be expressed in E. coli and purified by affinity chromatog-
raphy on an iminobiotin-sepharose matrix, highlighting its biotin-
binding affinity (See SI Figure S2 for details). To circumvent 
 poisoning of the precious metal cofactor by glutathione,47,48 we 
secreted the Sav-FPD chimera to the periplasm by fusing it with 
the OmpA N-terminal signal peptide. SDS-PAGE analysis of E. 
coli cells containing the OmpA-Sav-FPD construct confirmed 
localization of the soluble biotin-binding protein within its 
periplasm (Figure S1). As E. coli’s periplasm contains significant-
ly lower glutathione concentrations than the cytoplasm,49 and the 
equilibrium lies mostly to the oxidized disulfide form, we antici-
pated that [Cp*Ir(biot-p-L)Cl]   Sav-FPD would maintain its 
ATHase activity in the periplasm, as we have recently demon-
strated for metathesis using a biotinylated Ru-cofactor.47 
 
Figure 2. Introduction of an additional structural motif around the 
biotin-binding vestibule may influence the ATHase activity. (a) 
Sav-FPD chimera containing a cartoon representation of the FPD 
loop (in grey) and its sequence (in bold); residues highlighted in 
red were subjected to "saturation" mutagenesis. 
 
Five constructs were tested for the initial periplasmic screening: 
empty vector (as negative control), Sav WT, Sav-FPD, Sav 
K121A and Sav-FPD K121A. Following E. coli culture, the cells 
were incubated with the buffer containing [Cp*Ir(biot-p-L)Cl] and 
washed to remove the unbound cofactor (See SI for details). The 
cell pellet was resuspended in a solution containing formate (1 M) 
and substrate 1 (1 mM). Limited conversion (i.e. < 4 %) could be 
detected after 16 hours at 25 °C, either by fluorescence (322 nm 
excitation, 440 nm readout) or by UPLC-MS. Speculating that the 
low concentrations of glutathione present in the periplasm may 
suffice to irreversibly poison [Cp*Ir(biot-p-L)Cl], we added dia-
mide (2 mM) to fully oxidize glutathione.21,50 Again here, no 
conversion could be observed. Inspired by the Cu(II)-catalyzed 
glutathione oxidation,51,52 we washed the E. coli cells with 
[Cu(gly)2] (2 mM in MOPS buffer). To our delight, the uncaging 
of umbelliferone 2 was observed when this protocol was applied. 
Increasing the [Cp*Ir(biot-p-L)Cl] cofactor concentration from 1 
µM to 5 µM led to an increase in yield (Figure 3b). Thanks to the 
good Sav-FPD expression levels in E. coli’s periplasm, and the 
sensitivity of the fluorescence-based monitoring of catalysis, the 
entire screening procedure could be carried out in a 96-well plate 
format, Figure 4c. 
 
Figure 3. Assembling and screening ATHase in E. coli whole 
cells. (a) Localization of Sav-FPD chimeras within the periplasm 
of E. coli allows to screen whole cells for ATHase activity using 
the self-immolative quinolinium substrate 1. (b) Addition of 
[Cu(gly)2] significantly improves ATHase activity in E. coli. Bars 
show the mean of two independent replicate cultures with error 
bars indicating one standard deviation (See Table S10 for details).  
Past experience with [Cp*Ir(biot-p-L)Cl]   Sav highlighted the 
detrimental influence of K121 on ATHase activity.23,53 We hy-
pothesized that this residue may also affect catalytic activity of 
[Cp*Ir(biot-p-L)Cl]   Sav-FPD. Gratifyingly, the catalytic per-
formance of [Cp*Ir(biot-p-L)Cl]   Sav-FPD K121A was marked-
ly improved compared to [Cp*Ir(biot-p-L)Cl]   Sav-FPD and Sav 
K121A upon addition of 5 µM cofactor and 2 mM [Cu(gly)2], 
(33% yield and 5% yield for the Sav-FPD K121A and Sav-FPD-
ATHase respectively after 16 hours), Figure 3b. To determine the 
turnover numbers (TONs) of the ArMs within E. coli whole cells, 
these were subjected to ICP-MS analysis following the cell cul-
ture, incubation with the cofactor and washing (See SI for details). 
The following results were obtained: empty plasmid (0.15 nmol 
Ir, thus corresponding to 1 TON), Sav WT (0.36 nmol Ir, 11 
TON), Sav K121A (0.33 nmol Ir, 98 TON) and Sav-FPD K121A 
(0.48 nmol Ir, 137 TON) (Table S11).  
Next, we set out to optimize the catalytic activity by directed 
evolution relying on a 96 well plate assay. We built a mutant 
library relying on the NHT codons (that encode the A, N, D, H, I, 
L, F, P, S, T, Y and V amino acids) for mutations at the following 
positions: S112, K121, FPD(K9) and FPD(N11), Figure 2. The 
NHT primers code mostly for hydrophobic residues, which are 
known to positively influence the performance of ArMs.43,44  
In order to ensure full coverage at positions S112 and K121 
(i.e. 12   12 = 144 mutants), we mutated simultaneously both 
positions. Accordingly, 450 clones were screened and the best hits 
were sequenced. Eight independent biological replicates were 
tested revealing that Sav-FPD S112A-K121P performs best, 
followed by the Sav-FPD S112V-K121A. The low isolated yield 
resulting from the cytoplasmic expression of Sav-FPD S112A-
 K121P led us to select the better-behaved Sav-FPD S112V-
K121A as template for the next generation for FPD-centered 
mutagenesis. The positions K9 and N11, which are part of the 
FPD loop, were randomized sequentially using NHT codons. 
None of the triple or quadruple mutants screened outperformed 
[Cp*Ir(biot-p-L)Cl]   Sav-FPD S112V-K121A for the reduction 
of the quinolinium substrate 1 after screening 600 clones, Figure 
4.  
Next, Sav-FPD S112V-K121A was cocrystallized with 
[Cp*Ir(biot-p-L)Cl] (See SI for details). The structure was solved 
by molecular replacement. Comparison with the structure of 
[Cp*Ir(biot-p-L)Cl]   Sav S112A (PDB: 3PK2) reveals a shift of 
the 4,5-loop by 5.6 Å and a change in directionality of the 7,8-
loop, pointing towards the cofactor, Figure 5. The conformation 
of the 4,5-loop is stabilized through formation of ten new hydro-
gen bonds (Figure S4). The FPD-fragment could not be built due 
to insufficient electron density, presumably caused by its flexibil-
ity. The increased [Cp*Ir(biot-p-L)Cl] occupancy (i.e. 80%, com-
pared to 50% for related structures),39 suggests that the FPD-loop 
shields the biotin-binding vestibule and contributes to localize the 
cofactor. The proximity of two neighboring cofactors (Ir    Ir = 
5.3 Å in Sav monomers b and d in Figure 5) highlights the pres-
ence of a bridging chloride.  
 
Figure 4. Directed evolution of ATHase using the quinolinium 
substrate 1. (a) Screening results for "saturation" mutagenesis at 
positions S112, K121, FPD(K9) and FPD (N11) using NHT co-
dons. (b) 8-replicate comparison for the most promising mutants. 




Figure 5. Overlay of the X-ray crystal structure of [Cp*Ir(biot-p-
L)Cl]   Sav-FPD S112V-K121A (PDB: 6GMI) with [Cp*Ir(biot-
p-L)Cl]   Sav S112A (PDB: 3PK2). The protein is depicted as 
cartoon representation (monomer a of Sav-FPD S112V-K121A in 
blue, monomer b in green, monomer c in lilac and monomer d in 
cyan; Sav S112A in grey), the mutated residues S112V-K121A 
are depicted as magenta sticks. The bound [Cp*Ir(biot-p-L)Cl] 
cofactor is displayed as stick with the iridium as orange sphere 
(anomalous electron density: red mesh at 3s); chloride, green; 
sulfur, yellow; nitrogen, blue; oxygen, red. Structural features 
deviating from PDB 3PK2 are highlighted in pale red. The FPD-
fragment could not be fully resolved.  
 
The improved whole cell ATHase activity may result from a 
combination of two factors: i) improved activity of the Sav-FPD 
chimera and/or ii) higher protein expression level of the recombi-
nant protein in the periplasm. Screening with purified Sav sam-
ples in vitro, allows to deconvolute both factors. The in vitro 
ATHase activity towards four imines 4a – 7a and two quinolini-
ums 1 and 8a were tested. Results are summarized in Figure 6.  
Screening using purified Sav-FPD samples with prochiral sub-
strates 1 and 4a – 8a reveal several trends: i) Compared to Sav 
WT, introduction of the FPD structural motif (Sav-FPD) has a 
positive impact on the turnover numbers after 24 hours (TON). 
Up to a fivefold higher TON is observed in vitro for the salsoli-
dine precursor 4a. ii) We suggest that the difference in trends for 
the in vivo vs. purified ATHase reflects different production levels 
of the various mutants in the periplasm. iii) Introduction of muta-
tions at the base of loop 7,8 (i.e. Sav-FPD S112V-K121A) posi-
tively influences TON for three imine substrates: 5a, 6a, 7a and 
the quinolinium 1 and 8a. iv) These mutations also significantly 
influence enantioselectivity, especially in for imine 4a and quino-
linium 8a (See SI Table S8). It should be emphasized that the 
screening protocol focused on improving TON, not the enantiose-
lectivity. v) Mutations within the FPD motif have ambivalent 
effects: while Sav-FPD(K9L-N11P) S112V-K121A leads to a 
significant decrease in TON for all substrates, the Sav-FPD(K9I-
N11P) S112V-K121A affords good TON in most cases. It is 
striking how this conservative K9L to K9I mutation affects the 
catalytic performance.  
With the aim of developing a streamlined protocol for the di-
rected evolution of ATHases using E. coli whole cells, we report 
four important findings. i) Asymmetric transfer hydrogenation 
using the [Cp*Ir(biot-p-L)Cl]   Sav ArM can be performed in the 
periplasm of E. coli. We hypothesize that this contributes to oxi-
 dize the glutathione present in the periplasm. ii) The introduction 
of a loop in the immediate proximity of the biotin-binding vesti-
bule, combined with mutations within the 7,8-loop of Sav, has a 
positive effect on the performance of the engineered ATHase: up 
to 137 TON in E. coli whole cells and up to fivefold improvement 
using purified ATHases. iii) The performance of the ATHase can 
be improved by directed evolution using E. coli whole cells. Upon 
relying on the self-immolative substrate 1, the screening protocol 
can be carried out in a 96 well plate format. iv) The trends in TON 
observed for the self-immolative substrate 1 are reflected in the 
TON of substrates 4a – 8a. Current efforts are aimed adapting this 
protocol to improve both the activity and the (pseudo)-
enantioselectivity of ATHase. 
 
Figure 6. Substrate scope (TONs) for ATHase using mutants 
identified by self-immolative substrate 1. (See Table S8 for ee).  
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